Pasithea Therapeutics (KTTA) Retained Earnings (2021 - 2024)
Historic Retained Earnings for Pasithea Therapeutics (KTTA) over the last 4 years, with Q3 2024 value amounting to -$46.4 million.
- Pasithea Therapeutics' Retained Earnings fell 5330.21% to -$46.4 million in Q3 2024 from the same period last year, while for Sep 2024 it was -$46.4 million, marking a year-over-year decrease of 5330.21%. This contributed to the annual value of -$35.3 million for FY2023, which is 8245.99% down from last year.
- Per Pasithea Therapeutics' latest filing, its Retained Earnings stood at -$46.4 million for Q3 2024, which was down 5330.21% from -$43.0 million recorded in Q2 2024.
- Over the past 5 years, Pasithea Therapeutics' Retained Earnings peaked at -$2.2 million during Q4 2021, and registered a low of -$46.4 million during Q3 2024.
- Over the past 4 years, Pasithea Therapeutics' median Retained Earnings value was -$22.9 million (recorded in 2023), while the average stood at -$22.3 million.
- As far as peak fluctuations go, Pasithea Therapeutics' Retained Earnings plummeted by 77409.51% in 2022, and later crashed by 5330.21% in 2024.
- Quarter analysis of 4 years shows Pasithea Therapeutics' Retained Earnings stood at -$2.2 million in 2021, then plummeted by 774.1% to -$19.4 million in 2022, then plummeted by 82.46% to -$35.3 million in 2023, then crashed by 31.39% to -$46.4 million in 2024.
- Its last three reported values are -$46.4 million in Q3 2024, -$43.0 million for Q2 2024, and -$39.2 million during Q1 2024.